"Pyrazines" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
A heterocyclic aromatic organic compounds with the chemical formula C4H4N2.
| Descriptor ID |
D011719
|
| MeSH Number(s) |
D03.383.679
|
| Concept/Terms |
|
Below are MeSH descriptors whose meaning is more general than "Pyrazines".
Below are MeSH descriptors whose meaning is more specific than "Pyrazines".
This graph shows the total number of publications written about "Pyrazines" by people in this website by year, and whether "Pyrazines" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 2004 | 1 | 0 | 1 |
| 2005 | 0 | 1 | 1 |
| 2006 | 0 | 1 | 1 |
| 2008 | 0 | 1 | 1 |
| 2009 | 2 | 1 | 3 |
| 2010 | 1 | 0 | 1 |
| 2014 | 2 | 0 | 2 |
| 2017 | 1 | 0 | 1 |
| 2018 | 1 | 1 | 2 |
| 2021 | 1 | 2 | 3 |
| 2022 | 0 | 1 | 1 |
To return to the timeline,
click here.
Below are the most recent publications written about "Pyrazines" by people in Profiles.
-
Multi-organ dysfunction secondary to abrupt discontinuation of voxelotor in a patient with severe sickle cell disease. Am J Hematol. 2022 08; 97(8):E318-E320.
-
A Phase 1b Trial of Prexasertib in Combination with Standard-of-Care Agents in Advanced or Metastatic Cancer. Target Oncol. 2021 09; 16(5):569-589.
-
Preclinical Evaluation and Phase Ib Study of Prexasertib, a CHK1 Inhibitor, and Samotolisib (LY3023414), a Dual PI3K/mTOR Inhibitor. Clin Cancer Res. 2021 04 01; 27(7):1864-1874.
-
Genomic profiling is a supplemental diagnostic and therapeutic modality for hairy cell leukemia variant. Ann Hematol. 2021 06; 100(6):1629-1630.
-
Representation of the QM Subsystem for Long-Range Electrostatic Interaction in Non-Periodic Ab Initio QM/MM Calculations. Molecules. 2018 Sep 29; 23(10).
-
Evaluation of Prexasertib, a Checkpoint Kinase 1 Inhibitor, in a Phase Ib Study of Patients with Squamous Cell Carcinoma. Clin Cancer Res. 2018 07 15; 24(14):3263-3272.
-
Evaluating the Mechanism and Therapeutic Potential of PTC-028, a Novel Inhibitor of BMI-1 Function in Ovarian Cancer. Mol Cancer Ther. 2018 01; 17(1):39-49.
-
Management of a prediabetes case with the DPP-4 inhibitor sitagliptin. Ann Pharmacother. 2014 Jun; 48(6):811-5.
-
G(alpha)12/13 inhibition enhances the anticancer effect of bortezomib through PSMB5 downregulation. Carcinogenesis. 2010 Jul; 31(7):1230-7.
-
Proapoptotic activity of bortezomib in gastrointestinal stromal tumor cells. Cancer Res. 2010 Jan 01; 70(1):150-9.